At a glance
ClinicalIndex Comparison RecordN/ACompleted· 3,719 enrolled
Drug / intervention
vareniclinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets
In Brief
An observational study evaluating varenicline for Smoking Cessation. Completed, enrolled 3,719 participants.
Detailed Summary
To monitor use in real practice including safety and efficacy of Champix tablets 0.5mg, 1mg medication for 12 weeks in smokers
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
Countries--
Collaborators--
Timeline
N/ACompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2007
First PostedJun 2007
Primary CompletionMay 2011
TodayJul 2026
First PostedJun 6, 2007
Enrollment StartJun 1, 2007
Primary CompletionMay 1, 2011
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 19.1 years ago
Interventions
vareniclinedrug
As prescribed by physician in usual clinical practice.